TumorDiagnostik & Therapie

LinksSchließen

Referenz

Garon EB, Ciuleanu TE, Arrieta O et al.
Ramucirumab plus docetaxel vs. placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Lancet 2014;
384: 665-673

Bibliographische Angaben herunterladen

Suchen in:

Aufrufen in: